Histone deacetylase inhibitor suberoyl bis-hydroxamic acid suppresses cell proliferation and induces apoptosis in breast cancer cells

Molecular Medicine Reports

Volumn 11, Issue 4, 2015, Pages 2908-2912

  Yang, Xinmiao ^a   Zhang, Ning ^a   Shi, Zeliang ^b   Yang, Zhangyu ^b   Hu, Xichun ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Anticancer therapy; Bcl 2 family; Cell cycle arrest; Histone deacetylase

Indexed keywords

CYTOTOXIC AGENT; HISTONE DEACETYLASE INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; SUBEROYL BIS HYDROXAMIC ACID; UNCLASSIFIED DRUG; HYDROXAMIC ACID; SUBEROYL BIS-HYDROXAMIC ACID;

APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME CONDENSATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; IC50; MCF 7 CELL LINE; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; BREAST TUMOR; CELL CYCLE CHECKPOINT; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MCF-7 CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84921365138     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.3076     Document Type: Article

References (23)

1. Youlden DR, Cramb SM, Dunn N.A., Muller JM, Pyke CM and Baade PD: The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality. Cancer Epidemiol 36: 237-248, 2012.
2. Isakoff SJ: Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 16: 53-61, 2010.
3. Fukuda H, Sano N, Muto S and Horikoshi M: Simple histone acetylation plays a complex role in the regulation of gene expression. Brief Funct Genomic Proteomic 5: 190-208, 2006.
4. Federico M and Bagella L: Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol 2011: 47564, 2011.
5. Khan O and La Thangue NB: HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 90: 85-94, 2012.
6. Rikiishi H: Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011: 830260, 2011.
7. Mork CN, Faller DV and Spanjaard RA: A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des 11: 1091-1104, 2005.
8. Alao JP, Stavropoulou AV, Lam EW and Coombes RC: Role of glycogen synthase kinase 3 beta (GSK3beta) in mediating the cytotoxic effects of the histone deacetylase inhibitor tricho-statin A (TSA) in MCF-7 breast cancer cells. Mol Cancer 5: 40, 2006.
9. Lee YJ, Won AJ, Lee J, Jung J.H., Yoon S., Lee BM and Kim HS: Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Int J Med Sci 9: 881-893, 2012.
10. Ning L, Jaskula-Sztul R, Kunnimalaiyaan M and Chen H: Suberoyl bishydroxamic acid activates notch1 signaling and suppresses tumor progression in an animal model of medullary thyroid carcinoma. Ann Surg Oncol 15: 2600-2605, 2008.
11. You BR and Park WH: Suberoyl bishydroxamic acid inhibits the growth of A549 lung cancer cells via caspase-dependent apoptosis. Mol Cell Biochem 344: 203-210, 2010.
12. Zhuang ZG, Fei F, Chen Y and Jin W: Suberoyl bis-hydroxamic acid induces p53-dependent apoptosis of MCF-7 breast cancer cells. Acta Pharmacol Sin 29: 1459-1466, 2008.
13. Hrabeta J, Stiborova M, Adam V., Kizek R and Eckschlager T: Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2013 158: 161-169, 2014.
14. Yoon MK, Mitrea DM, Ou L and Kriwacki RW: Cell cycle regulation by the intrinsically disordered proteins p21 and p27. Biochem Soc Trans 40: 981-988, 2012.
15. Jiang D, Wang X, Liu X and Li F: Gene delivery of cyclin-dependent kinase inhibitors p21 (Waf1) and p27 (Kip1) suppresses proliferation of MCF-7 breast cancer cells in vitro. Breast Cancer 21: 614-623, 2013.
16. Wei M, Liu B, Gu Q., Su L, Yu Y and Zhu Z: Stat6 cooperates with Sp1 in controlling breast cancer cell proliferation by modulating the expression of p21 (Cip1/WAF1) and p27 (Kip1). Cell Oncol (Dordr) 36: 79-93, 2013.
17. Greenblatt DY, Cayo M, Ning L., et al.: Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J Gastrointest Surg 11: 1515-1520, 2007.
18. Zhang L and Yu J: Role of apoptosis in colon cancer biology, therapy, and prevention. Curr Colorectal Cancer Rep 9, 2013.
19. Beckta JM, Ahmad SF, Yang H and Valerie K: Revisiting p53 for cancer-specific chemo- and radiotherapy: Ten years after. Cell Cycle 13, 2014.
20. Cregan SP, MacLaurin JG, Craig C.G., Robertson GS, Nicholson DW, Park DS and Slack RS: Bax-dependent caspase-3 activation is a key determinant in p53-induced apoptosis in neurons. J Neurosci 19: 7860-7869, 1999.
21. Wang J, Kim TH, Ahn M.Y., et al.: Sirtinol, a class III HDAC inhibitor, induces apoptotic and autophagic cell death in MCF-7 human breast cancer cells. Int J Oncol 41: 1101-1109, 2012.
22. Danial NN: BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 13: 7254-7263, 2007.
23. Chen S, Dai Y, Pei XY and Grant S: Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1. Mol Cell Biol 29: 6149-6169, 2009.